Bronnen:
- Dimopoulos MA, Gay F, Schjesvold F, et al.; TOURMALINE-MM3 study group. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2018 Dec 10. ,Van de Donk NWCJ, Yong K. Oral proteasome inhibitor maintenance for multiple myeloma. Lancet. 2018 Dec 10.,McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366:1770-81.,Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366:1782-91.,Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895-905.,Jackson G, Davies F, Pawlyn C, et al. Lenalidomide maintenance significantly improves outcomes compared to obervation irrespective of cytogenetic risk: results of the Myeloma XI trial. Blood. 2017;130(suppl 1):436.,McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279-89.